Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Lo Studio RHINO (Rhinovirus Hospitalization and Investigation of Nasal-airway Omics)

10 novembre 2026 aggiornato da: University of Wisconsin, Madison

Identificazione del Peso Ospedaliero Causato dal Rhinovirus (RV) nei Bambini e Meccanismi di Patogenesi Utilizzando la Profilazione Molecolare delle Vie Aeree

The goal of this study is to determine the burden of Rhinoviruses (RVs) as a cause of acute, severe, respiratory illnesses leading to hospitalization. A community cohort of 120 children between 12 and 36 months of age will be enrolled in the first year of the study and followed (when well and sick) for 36 months to identify the circulating RVs and provide samples to establish a host nasal transcriptome differentiating clinical from subclinical RV infections. A hospitalized cohort of 450 infants and children will be enrolled during years 1 through 3 of the study and followed for the duration of their hospitalization to investigate the findings of the community cohort. An additional 100 healthy children aged 5-17.5 years will be enrolled for age-match comparison with the older hospitalized cohort.

Panoramica dello studio

Descrizione dettagliata

Aim 1: Involves the prospective creation of a cohort of generally healthy children 12 to 36 months to be followed longitudinally for 36 months in an observational study. To determine the frequency of virus infection with RV and other respiratory viruses, children will have two swabs of the nasal mucosa performed whenever they develop an acute respiratory illness (upper respiratory symptoms lasting more than 24 hours) and four times a year for surveillance. One swab will be of the anterior nose and will be used for identification of viruses, and a second mid-turbinate swab will be used for host transcriptomics. This will allow the investigators to create many samples from both symptomatic and asymptomatic infections. The samples will be used to develop a host signature to discriminate symptomatic and asymptomatic infection.

Aim 2a: Involves the evaluation of generally healthy children hospitalized at AFCH with acute, lower respiratory tract infections including bronchiolitis, asthma, acute hypoxemic respiratory failure and community acquired pneumonia. There will also be the evaluation of infants less than 6 months of age who may become ill with an RV syndrome. These children will be evaluated with two nasal swabs as above. This allows the identification of children infected with RV and other respiratory viruses. Application of the host signature developed in Aim 1 will determine the actual proportion of those children who are infected with RV whose illness (clinical symptoms) is caused by RV.

Aim 2b: Involves the prospective creation of a cohort of generally healthy children 5 to 17.5 years old to be sampled on an as-needed basis to serve as age- and season-matched controls for the Hospitalized Group. To determine the frequency of virus infection with RV and other respiratory viruses, 2 healthy children will provide a single swab of the nasal mucosa within 2 weeks of each hospitalized participant who is 5-17.5 years of age. The one swab will be of the anterior nose and will be used for identification of viruses. Age matching will occur within 3 groups:

  • Ages 5-8 years old: n=50
  • Ages 9-13 years old: n=30
  • Ages 14-17.5 years old: n=20

Aim 3: Use parallel bulk and single cell RNA sequencing (scRNA-seq) to identify targetable processes of acute, severe LRT caused by RV. The investigators hypothesize that integrated bulk RNA-sequencing and scRNA-seq will identify immune/inflammatory defects and targets for intervention. Bulk and scRNA-seq on respiratory samples from well-characterized patients with severe RV disease will be performed to test this hypothesis and to compare samples obtained from those with non-severe disease.

Tipo di studio

Osservativo

Iscrizione (Stimato)

670

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Wisconsin
      • Madison, Wisconsin, Stati Uniti, 53792
        • Reclutamento
        • University of Wisconsin

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Non più vecchio di 17 anni (Bambino)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Aim 1: Generally healthy male and female children 12 to 36 months of age living in Dane County and surrounding areas representative of the general demographics of the county.

Aim 2a: Hospitalized male and female children between newborn and 17.5 years of age with acute onset lower respiratory tract infections. These children will span all demographic and socioeconomic groups.

Aim 2b: Generally healthy male and female children 5 to 17.5 years of age living in Dane County and surrounding areas representative of the general demographics of the county.

Descrizione

Inclusion Criteria (Aim 1 and Aim 2b Community Groups):

  • Parent/legal guardian is willing and able to provide informed consent in English.
  • Willing to comply with all study procedures and be available for the duration of the study.
  • Younger Community Group: Generally healthy children 12 to 36 months of age at the time of enrollment
  • Older Community Group: Generally healthy children 5 to 17.5 years of age at the time of enrollment.
  • Current patient within primary care system at UW Health

Inclusion Criteria (Aim 2a: Hospitalized Group):

  • Parent/legal guardian is willing and able to provide informed consent in English.
  • Admitted to American Family Children's Hospital (AFCH) within the past 24 hours or have been assigned an admission-related status (including "Admit Probable" or "IP Bed Requested") that reflects an expected inpatient admission.
  • Children under 17.5 years of age at the time of enrollment
  • Has a diagnosis of bronchiolitis, asthma exacerbation, acute hypoxemic respiratory failure or community acquired pneumonia (CAP) OR is an infant less than 6 months of age with fever greater than 38 degrees Celsius within 24 hours of hospital admission

Exclusion Criteria (all participants):

  • Congenital or currently acquired immunosuppressive condition or medications (e.g., congenital immunodeficiency, Leukemia, Lupus)
  • Congenital anomalies that might alter frequency of infection (e.g., unrepaired cleft palate, bronchial cyst, pulmonary sequestration)
  • Presence of tracheostomy or gastrostomy tube
  • Previously enrolled a different group in the study
  • Other child in the same household already enrolled in the study
  • Not suitable for study participation due to other reasons at the discretion of the investigators.

Exclusion Criteria (Aim 1: Community Group Only):

  • History of chronic pulmonary diseases (e.g., asthma, cystic fibrosis, bronchopulmonary dysplasia (BPD)) (Note: asthma IS exclusionary), reactive airway disease within the Older Community Group is not exclusionary unless they have a maintenance inhaler.
  • Acute upper respiratory symptoms within the past week (7 days) at the time of enrollment

Exclusion Criteria (Aim 2: Hospitalized Group Only):

  • History of chronic pulmonary diseases, excluding asthma (e.g., cystic fibrosis, bronchopulmonary dysplasia (BPD)) (Note: asthma is NOT exclusionary)
  • A positive test for any other respiratory virus other than RV within the 48 hours prior to and including admission documented at the time of consent. (Note: Negative for rhinovirus is not exclusionary).
  • Non-respiratory infection at the time of admission (e.g. Bacteremia) (Note: UTI, Osteomyelitis, Otitis media, and MRSA colonization is not exclusionary.)
  • Uncontrolled and/or profound neurologic disease, as determined by the investigator or designee at time of admission, considering factors such as uncontrolled seizures, inability to ambulate, inability to communicate verbally, or dependence on a gastrostomy tube (G-tube) or ventilatory assistance (e.g., positive pressure ventilation) (e.g., cerebral palsy, genetic neurologic diseases).

Exclusion Criteria (less than 5 years old only (All participants in Aim 1 and some participants in Aim 2a):

  • Born prematurely, less than 32 weeks 0 days gestational age

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Younger Community Cohort (12-36 months of age)

Quarterly Surveillance Nasal Swabs and Nasal Swabs targeted around respiratory symptoms for up to 36 months of age, participants will provide one anterior and one mid-turbinate nasal swab sample

Families will be asked to collect nasal swabs from their children during specified surveillance months (February, April, September, and December). Caregivers will be instructed to only collect surveillance samples during these months if and when children have been free of respiratory symptoms for at least two weeks prior to sampling. Caregiver surveys are part of quarterly surveillance.

Caregivers will be instructed to watch for respiratory symptoms and collect nasal swabs 24-48 hours after symptom onset. Caregiver surveys are part of sick sample collection

Caregivers are surveyed 7-13 days after sick sample collection

Hospitalized Cohort of Infants and Children

Generally healthy infants and children hospitalized for respiratory illness will provide one anterior and one mid-turbinate nasal swab sample

2 nasal swabs collected upon consent, one anterior and one mid-turbinate

For hospitalized participants who opt to induce sputum, 3 medications will be used to obtain the sample, albuterol sulfate solution and hypertonic saline (3% solution) administered via nebulizer and and lidocaine spray (4% solution) via atomizer to the nose. For hospitalized participants with pneumonia who opt for research blood draw or induced sputum, optional administration of oral sucrose (Sweet-Ease) may occur at the discretion of the treating provider.

Altri nomi:
  • Soluzione salina ipertonica
  • Dolce facilità
  • Spray alla lidocaina
  • Albuterol sulfate solution
Older Community Cohort (5 to 17.5 years of age)

Age-matched controls for older children in the Hospitalized Group, will be called upon as needed based on enrollment of hospitalized patients

Participants will be enrolled as needed based on enrollment of hospitalized patients

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Obiettivo 1: Firma trascrittomica nasale unica delle infezioni cliniche da rinovirus
Lasso di tempo: dati raccolti fino a 36 mesi
dati raccolti fino a 36 mesi
Aim 1: Summary of Rhinovirus Types Identified in Community Cohort
Lasso di tempo: data collected up to 36 months

To test study hypotheses, the study team will identify the circulating RV types in symptomatic and asymptomatic children.

data collected up to 36 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Aim 2: Summary of Rhinovirus Types Identified in lower respiratory tract (LRT) infections and upper respiratory tract infections (URI), Reported as Percent in Common
Lasso di tempo: data collected up to 36 months

To test the hypothesis that there will be an 80 percent overlap between RV types causing acute LRT and URI, investigators will compare all RV types identified in age-matched hospitalized and ambulatory children.

data collected up to 36 months
Aim 2: Proportion of Hospitalized Cohort with lower respiratory infections attributable to Rhinovirus
Lasso di tempo: data collected up to 36 months

The investigators will use host nasal transcriptomics derived from symptomatic and asymptomatic children with RV infection to determine the proportion of age-matched hospitalized LRT infections actually attributable to RV.

data collected up to 36 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Ellen R Wald, MD, UW School of Medicine and Public Health

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 agosto 2026

Completamento primario (Stimato)

1 maggio 2030

Completamento dello studio (Stimato)

1 maggio 2030

Date di iscrizione allo studio

Primo inviato

13 gennaio 2026

Primo inviato che soddisfa i criteri di controllo qualità

13 gennaio 2026

Primo Inserito (Effettivo)

15 gennaio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2025-1076
  • SMPH\PEDIATRICS\INFECT DIS (Altro identificatore: UW Madison)
  • 1R01AI182200-01A1 (Sovvenzione/contratto NIH degli Stati Uniti)
  • Protocol Version 8/25/26 (Altro identificatore: UW Madison)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

This study will comply with the NIH Genomic Data Sharing Policy, which applies to all NIH-funded research that generates large-scale human or non-human genomic data, as well as the use of these data for subsequent research. Large-scale data include genome-wide association studies (GWAS), single nucleotide polymorphisms (SNP) arrays, and genome sequence, transcriptomic, epigenomic, and gene expression data.

Periodo di condivisione IPD

Data from this study may be requested from other researchers 3 years after the completion of the primary endpoint by contacting the study team at UW-Madison.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi